H1 2024 ADC Landscape Review

In just the first half of 2024, the ADC landscape has expanded by 21%, driven by innovations in dual-targeting ADCs and a shift towards topoisomerase I inhibitors, which now make up 56% of new drug entries. With such rapid growth, understanding these trends is crucial for staying competitive.

Our H1 2024 Landscape Review provides you with essential data and analyses, including insights into the growing interest in B7-H3, HER-3, and dual-targeting drugs. With 300 new ADC trials identified this year and notable drugs like izalontamab brengitecan and sacituzumab tirumotecan leading clinical studies, our report ensures you have the knowledge needed to drive successful drug development.

Part 1 – The Drug Landscape

Download Here

Part 2 – The Trial Landscape & Regulatory Announcements

Download Here

Part 3 – The Commercial Landscape & Future of ADCs

Coming Soon

What do these reviews cover?

Our 2024 ADC Landscape Review provides a comprehensive analysis of the current state of the ADC field, including:

The Drug Landscape – Discover the emergence of new ADC targets, including a 21% growth in new assets and a notable shift towards bispecific ADCs and topoisomerase I inhibitors, reflecting ongoing innovation and the expanding complexity of the ADC field.
The Trial Landscape & Regulatory Announcements – Gain insights into the significant increase in clinical trial activity, with a 53% year-over-year rise in new trials and a surge in late-stage clinical trials. Understand the challenges developers face, including the difficulty of achieving new approvals and the critical role of adaptive trial designs and biomarker-driven strategies.
The Commercial Landscape & Future of ADCs – Explore the evolving investment landscape, where funding is increasingly directed toward late-stage ADCs positioned for market entry, while early-phase investments target emerging technologies and novel ADC targets. Understand the strategic partnerships driving innovation and growth in 2024.

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.

Discover more about Beacon